Orris

Optic neuritis

Reading File
Finding Sources
Searching Images

optic neuritis fundus clinical features

Reading File
Reading File
Reading File
Finding Sources
Loading Image
Reading File
Reading File
Here is a comprehensive overview of optic neuritis, drawn from multiple authoritative sources.

Optic Neuritis

Definition & Pathophysiology

Optic neuritis is an inflammatory optic neuropathy most commonly caused by demyelinating disease. Demyelination disrupts nerve conduction within the white matter; myelin is phagocytosed by microglia and macrophages, with astrocytes subsequently laying down fibrous tissue in plaques. — Kanski's Clinical Ophthalmology, 10th ed.

Clinical Features

FeatureDetail
Visual lossTypically monocular; onset over hours to a few days; can range from mild reduction to no light perception
PainPeriocular pain worsening with eye movement in ~90% of cases; typically lasts 3–5 days
Color visionImpaired out of proportion to acuity; red desaturation (red object appears pink in affected eye)
Visual fieldDiffuse depression or discrete scotomas (non-specific)
Afferent pupillary defect (APD)Commonly present
FundusNormal in ~70% (retrobulbar neuritis); disc edema (papillitis) in ~30% — mild, less prominent than papilledema
Pain persisting >7 days should prompt reconsideration of the diagnosis. — Bradley and Daroff's Neurology in Clinical Practice

Fundus Findings

Fundus photographs showing acute left optic neuritis (A) with mild nerve fiber layer edema at the nasal disc, and resolution at 3 months (B) with mild temporal pallor
Fig. A — Acute optic neuritis: mild nasal disc edema, no hemorrhages or cotton-wool spots. B — Same eye 3 months later: edema resolved, mild temporal pallor indicating axonal loss. — Bradley and Daroff's Neurology in Clinical Practice

Etiology

  • Idiopathic / Multiple sclerosis — most common
  • NMOSD (Devic disease) — antibodies against aquaporin-4; bilateral optic neuritis + long-segment transverse myelitis
  • MOGAD — antibodies against myelin oligodendrocyte glycoprotein; bilateral simultaneous optic neuropathy is a common feature
  • Infections — measles, mumps, varicella, herpes zoster, EBV, syphilis, TB, cryptococcosis
  • Post-vaccination (especially childhood vaccines)
  • Contiguous inflammation — meningitis, orbital cellulitis, sinusitis
  • Sarcoidosis
— Tintinalli's Emergency Medicine

Investigations

TestFinding
MRI brain (gadolinium)White matter plaques; optic nerve enhancement on STIR/fat-sat T1 sequences; key prognosticator for MS risk
MRI orbitsOptic nerve swelling and T2 hyperintensity
VEPProlonged latency and reduced amplitude — abnormal in up to 100% of MS-associated cases
OCTRetinal nerve fiber layer (RNFL) and ganglion cell layer atrophy post-episode
CSFOligoclonal bands in 90–95% of MS-associated cases
NMO-IgG (anti-AQP4)Positive in ~70% of NMOSD — highly specific

Risk of Progression to MS

  • Overall 15-year risk: ~50% after a first optic neuritis episode
  • With ≥1 MRI brain lesion: risk >70%
  • With normal MRI: risk ~25%
Factors associated with lower MS risk (especially if MRI is normal):
  • Male sex
  • Optic disc swelling, disc/peripapillary hemorrhages, or macular exudates
  • Vision reduced to no light perception
  • Absent periocular pain
  • No preceding viral syndrome
  • Negative EBV serology
Optic neuritis is the presenting feature of MS in up to 30% of MS patients, and occurs at some point in 50% of established MS cases. — Kanski's Clinical Ophthalmology

Differential Diagnosis

ConditionKey Distinguishing Feature
Anterior ischemic optic neuropathy (AION)Sudden, painless; older patients; pallid disc edema (GCA) or hyperemic (non-arteritic)
PapilledemaBilateral; painless; visual acuity preserved until late
Hypertensive retinopathySystemic hypertension; bilateral
Orbital/intracranial tumorProptosis; visible on CT/MRI
Toxic/metabolic optic neuropathyAlcohol, heavy metals, chloroquine — bilateral, painless
LHONPeripapillary telangiectatic microangiopathy; mitochondrial genetics

Treatment

Acute:
  • IV methylprednisolone (high-dose) — hastens visual recovery; reduces short-term MS risk over the following 2 years, but does not significantly affect long-term visual outcomes
  • Oral prednisone alone (1 mg/kg) should be avoided — associated with increased risk of recurrence
  • For NMOSD: high-dose IV steroids → oral taper; plasmapheresis if steroid-refractory
Disease-modifying therapy (MS prevention):
  • Early immunomodulatory treatment in high-risk patients (MRI lesions) to reduce 2–5 year MS risk
  • NMOSD-specific agents: eculizumab, inebilizumab, satralizumab (for anti-AQP4+ patients); rituximab

Prognosis

  • Visual recovery generally begins within 1 month; prognosis correlates with severity of initial deficit
  • In MS-associated optic neuritis, vision usually improves without treatment over several months
  • Post-episode OCT typically shows RNFL atrophy — a reliable structural marker of axonal loss even after clinical recovery
Sources: Bradley and Daroff's Neurology in Clinical Practice | Kanski's Clinical Ophthalmology, 10th ed. | Tintinalli's Emergency Medicine | Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.